Market Cap 313.86M
Revenue (ttm) 22.60M
Net Income (ttm) -86.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -383.27%
Debt to Equity Ratio 0.00
Volume 73,400
Avg Vol 227,754
Day's Range N/A - N/A
Shares Out 56.55M
Stochastic %K 68%
Beta 3.04
Analysts Strong Sell
Price Target $11.67

Company Profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cel...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 586 3100
Address:
500 Technology Square, Suite 700, Cambridge, United States
CoalKingpin
CoalKingpin Dec. 24 at 10:50 AM
$FHTX Current positioning will be tested as strategic priorities translate into measurable operating outcomes. The window for proof-of-execution is narrowing.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 4:09 PM
$FHTX RSI: 78.83, MACD: 0.2319 Vol: 0.43, MA20: 4.69, MA50: 4.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
AnomalyDetective
AnomalyDetective Dec. 22 at 6:07 PM
$FHTX the first of the Week 52 MDA picks for members to break 10% through Monday in this short trading week. Many more prior MDA breakout picks available at top.vmbreakouts.com Credit: vmbreakouts.com @vmbreakouts More on the new 2026 portfolios here: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6238776-a-glimpse-of-portfolios-to-come-for-2026
0 · Reply
notreload_ai
notreload_ai Dec. 18 at 5:27 PM
$ALMS , $FHTX , $LXEO ... Analysts highlight Alumis, Foghorn, and Lexeo as biotech stocks with strong clinical catalysts and significant upside potential into 2026. https://notreload.xyz/biotech-analyst-picks-signal-major-upside-into-2026/
0 · Reply
vu_jade
vu_jade Dec. 18 at 5:00 PM
$FHTX is this the “Leg Horn” part?
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 12:19 PM
BTIG has updated their rating for Foghorn Therapeutics ( $FHTX ) to Buy with a price target of 11.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 17 at 9:51 PM
$FHTX Share Price: $4.63 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $0.72 – $0.89 Target Zone: $1.26 – $1.54 Potential Upside: 65% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Baerchen
Baerchen Dec. 17 at 6:18 PM
$FHTX prelude was working afasi on a single asset-therapy - when working through fhtx-presentation, you easily spot, they take their smarca2 with name olomorasib and 2 further lly-assets as well as with chemo-standard. Only one positive trial will get new SOC. There is a reason why LLY does this and probably spent even more. It is the same as it was in KRAS. Many failed - but once a therapy got breakthrough, they lead. From all bios out in the stock market - this is a gem.
1 · Reply
theBigDollarski
theBigDollarski Dec. 16 at 3:20 PM
$FHTX this is so cheep it's laughable.
0 · Reply
Woodmont
Woodmont Dec. 16 at 12:51 PM
$FHTX If the lead drug is proven effective, LLY will buy the whole company at 10x from where we are sitting today, slowly accumulating good luck!!!
0 · Reply
Latest News on FHTX
Foghorn Therapeutics: Ifs, Buts, And Clinical Holds

Aug 16, 2023, 5:08 PM EDT - 2 years ago

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds


CoalKingpin
CoalKingpin Dec. 24 at 10:50 AM
$FHTX Current positioning will be tested as strategic priorities translate into measurable operating outcomes. The window for proof-of-execution is narrowing.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 4:09 PM
$FHTX RSI: 78.83, MACD: 0.2319 Vol: 0.43, MA20: 4.69, MA50: 4.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
AnomalyDetective
AnomalyDetective Dec. 22 at 6:07 PM
$FHTX the first of the Week 52 MDA picks for members to break 10% through Monday in this short trading week. Many more prior MDA breakout picks available at top.vmbreakouts.com Credit: vmbreakouts.com @vmbreakouts More on the new 2026 portfolios here: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6238776-a-glimpse-of-portfolios-to-come-for-2026
0 · Reply
notreload_ai
notreload_ai Dec. 18 at 5:27 PM
$ALMS , $FHTX , $LXEO ... Analysts highlight Alumis, Foghorn, and Lexeo as biotech stocks with strong clinical catalysts and significant upside potential into 2026. https://notreload.xyz/biotech-analyst-picks-signal-major-upside-into-2026/
0 · Reply
vu_jade
vu_jade Dec. 18 at 5:00 PM
$FHTX is this the “Leg Horn” part?
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 12:19 PM
BTIG has updated their rating for Foghorn Therapeutics ( $FHTX ) to Buy with a price target of 11.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 17 at 9:51 PM
$FHTX Share Price: $4.63 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $0.72 – $0.89 Target Zone: $1.26 – $1.54 Potential Upside: 65% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Baerchen
Baerchen Dec. 17 at 6:18 PM
$FHTX prelude was working afasi on a single asset-therapy - when working through fhtx-presentation, you easily spot, they take their smarca2 with name olomorasib and 2 further lly-assets as well as with chemo-standard. Only one positive trial will get new SOC. There is a reason why LLY does this and probably spent even more. It is the same as it was in KRAS. Many failed - but once a therapy got breakthrough, they lead. From all bios out in the stock market - this is a gem.
1 · Reply
theBigDollarski
theBigDollarski Dec. 16 at 3:20 PM
$FHTX this is so cheep it's laughable.
0 · Reply
Woodmont
Woodmont Dec. 16 at 12:51 PM
$FHTX If the lead drug is proven effective, LLY will buy the whole company at 10x from where we are sitting today, slowly accumulating good luck!!!
0 · Reply
vu_jade
vu_jade Dec. 8 at 8:42 PM
$FHTX Doing some Leghorn work
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 4:57 PM
Stifel has adjusted their stance on Foghorn Therapeutics ( $FHTX ), setting the rating to Buy with a target price of 12.
0 · Reply
notreload_ai
notreload_ai Dec. 3 at 10:43 PM
Stifel starts $FHTX coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with $LLY expected to launch in 2030 with strong sales potential. https://notreload.xyz/stifel-bullish-on-foghorn-therapeutics-stock/
0 · Reply
Stmkr
Stmkr Nov. 17 at 3:58 PM
$FHTX What is going on here today?
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 17 at 12:27 AM
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 4:29 PM
Guggenheim updates rating for Foghorn Therapeutics ( $FHTX ) to Buy, target set at 12.
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 7 at 1:59 PM
+Initiations 11/7: $AARD $CNOB $FHTX $IMUX . -Initiations 11/7:
0 · Reply
LabPsycho
LabPsycho Nov. 5 at 5:42 PM
$FHTX Smarca2 as their lead...hmmm......look at PRLD and their smarca2 that they just seemingly tossed yesterday...
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 5 at 12:21 PM
$FHTX Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 4 at 2:26 PM
$FHTX fyi... prelude deprioritized their smarca2 program. this may have read through to foghorn's program. i think there other preclinical programs seem interesting and assume the lilly partnership could be maintained, if they also decide to deprioritize their smarca2 and pivot to another program. with that said, if they also announce a deprioritization, expect the stock price to drop. could be a good time to buy, at that time. wait for q3 er. “Having actively pursued the clinical development of our SMARCA2 selective degraders, we determined that complex biology and aggressiveness of disease in patients with SMARCA4 deletions will likely require early intervention and combination strategies to make a meaningful impact for patients." Prelude CEO
1 · Reply
LabPsycho
LabPsycho Nov. 4 at 2:23 PM
$FHTX @Baerchen 'partner with any Chinese or PD-L1 company....get any results you want [if the price is right!) Lol
0 · Reply
PaulLaurent
PaulLaurent Nov. 1 at 7:34 PM
🧭 Weekly Swing Recap $FHTX – Exceeded the target zone by $0.22. Clean execution; trims into strength worked. $IPHA – Target zone hit, but you had to be fast. Always place sells in the target zone—don’t wait for a unicorn (500%+). $NRGV – +14% from the entry; target not reached but still a profitable push. $NLSP$NCEL – +70% from the entry. Merger volatility knocked it after—lock gains when you have them. $ZENA – Never reached the entry zone—no entry. Tone: Discipline wins. Pre-set brackets, favor VWAP/pivot reclaims, scale out into strength, and protect gains if momentum cools.
3 · Reply